Recent human genetic studies have revealed that dysfunction in microglia is associated with the development of Alzheimer's disease (AD), and that the receptor TREM2 is a key regulator of microglial activity. Mutations in TREM2 that reduce its function increase the risk of developing AD while complete loss of TREM2 causes a rare neurodegenerative disorder, demonstrating the importance of TREM2-mediated microglial activity in maintaining functionality of the aging brain. TREM2 is an immune cell activating receptor that binds ligands exposed by apoptotic neurons, degrading myelin or amyloid plaques. Loss of TREM2 signaling causes reduced microglial viability, proliferation and activation. We sought to develop TREM2 agonistic antibodies to increase TREM2 signaling in AD patient brains to improve the ability of microglia to clear pathological proteins and protect neurons with the goal to halt progression of the disease. We utilized hybridoma and Adimab yeast platforms to identify TREM2 binding antibodies. Antibodies were screened for their ability to activate TREM2 signaling in a reporter cell assay and primary myeloid cells in vitro, as well as for their ability to activate signaling in vivo. To test the effects of TREM2 antibodies on brain microglia, they were injected peripherally into mice expressing human TREM2. Microglial proliferation and abundance was assessed by immunohistochemistry and tissue RNAseq. Finally, TREM2 antibodies were chronically administered to 5xFAD AD model mice to test if TREM2 activation can impact AD pathology. We have identified antibodies that activate TREM2 signaling both in a reporter cell assay and in macrophages in vitro. Peripheral injection of these antibodies triggers TREM2 signaling, microglial proliferation and activation in mouse brains. These data suggest that the antibodies efficiently cross the blood-brain barrier and that TREM2 signal induction is sufficient to shift the microglia phenotype. In 5xFAD mice, chronic treatment with a TREM2 agonist causes increased expression of synaptic and myelin genes. Our data suggest that TREM2 agonistic antibodies could reverse microglial dysfunction in AD patients. Alector's lead antibody AL002 is currently in phase I clinical trials, being assessed for safety, PK and brain target engagement in healthy subjects and AD patients.